secwatch.observer — SEC 8-K summary
======================================

Issuer:     IO Biotech, Inc. (IOBTQ)
CIK:        0001865494
Form:       8-K
Filed at:   2024-08-13T23:59:59+00:00
Accession:  0001193125-24-199383
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IO Biotech Q2 net loss $20.7M; cash runway into Q4 2025; Phase 3 interim analysis expected Q3 2024
--------------------------------------------------------------------------------

- Net loss of $20.7M for Q2 2024 vs $21.2M in Q2 2023; R&D expenses $15.8M.
- Cash and equivalents $100.7M at June 30, 2024, down from $143.2M at year-end 2023.
- Phase 3 trial (IOB-013) interim analysis for ORR expected Q3 2024; primary PFS endpoint in H1 2025.
- Potential BLA submission in Q4 2024 if interim analysis supports accelerated approval.
- Completed enrollment in Phase 2 basket trial (IOB-022) for NSCLC and SCCHN; data to be presented at ESMO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1865494/000119312524199383/0001193125-24-199383-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1865494/000119312524199383/d894513d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-199383

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer